(Total Views: 678)
Posted On: 03/29/2021 9:09:51 AM
Post# of 154867
Ohm,
Correct, we need to bear in mind that HGEN did not power their trial for mortality end-point.
They say that will the data they have in-hand they would need app. 1800 patients for this (as opposed to app 6000 in Dexamethasone and app 4000 Tocilizumab) with a 80% power.
They obtained a Hazard ratio of 1.54 (p-value: 0.0365) in Ventilator-free survival.
I believe this is what we will have as PE in our CD-16 trial for Critical.
Correct, we need to bear in mind that HGEN did not power their trial for mortality end-point.
They say that will the data they have in-hand they would need app. 1800 patients for this (as opposed to app 6000 in Dexamethasone and app 4000 Tocilizumab) with a 80% power.
They obtained a Hazard ratio of 1.54 (p-value: 0.0365) in Ventilator-free survival.
I believe this is what we will have as PE in our CD-16 trial for Critical.
(3)
(0)
